Calliditas Therapeutics
Supin Koo, PhD has extensive work experience in the field of medical affairs and medical science liaison roles. They are currently serving as the Director of Medical Affairs (United States) at Calliditas Therapeutics since 2022. Prior to this, they worked at Amgen for over 17 years, starting in 2004. At Amgen, they held the position of Director of Medical Science Liaisons from 2009 to 2021 and Senior Medical Science Liaison from 2004 to 2009. Before joining Amgen, they worked at Sanofi-Synthélabo Ltd. as a Medical Science Liaison from 2001 to 2003.
Supin Koo, PhD has a diverse educational background in the field of biology and infectious diseases. Supin pursued their education at various prestigious institutions. Supin started their educational journey at UNSW, where they earned a Bachelor of Science (Honors) degree in Medical Microbiology. Following this, they continued their studies at the University of Aberdeen, where they successfully completed their Doctor of Philosophy (PhD) in Cellular and Molecular Biology. Lastly, they conducted postdoctoral research at UCLA, focusing on the field of Infectious Disease. The chronological order of their education history is as follows: Bachelor of Science (Honors) in Medical Microbiology at UNSW, Doctor of Philosophy (PhD) in Cellular and Molecular Biology at the University of Aberdeen, and postdoctoral research in Infectious Disease at UCLA.
This person is not in any offices
Calliditas Therapeutics
2 followers
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.